Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva bupropion

Executive Summary

First generic version of Glaxo Wellcome's antidepressant is launched at a 10% discount to the brand ($72.08 for 100-count 75 mg tablets and $96.16 for 100-count 100 mg tablets). Teva's ANDA was approved Nov. 29 following a Nov. 19 settlement of patent litigation brought by Glaxo. The settlement involved a license to Teva to manufacture its own version of the product. Glaxo has also settled litigation with Watson over the product

You may also be interested in...



Glaxo Zyban/Wellbutrin DTC Accounts Move To Grey Advertising

The award of Glaxo's bupropion franchise to Grey Advertising consolidates six of the firm's nine DTC-advertised products into one agency.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel